Moomoo AI 已提取核心信息
SciSparc Ltd., a clinical-stage pharmaceutical company, announced on February 29, 2024, the successful delivery of its SCI-210 treatment for a clinical trial targeting Autism Spectrum Disorder (ASD) in pediatric patients. The trial, to be conducted at the Soroka Medical Center, will test the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy. SCI-210 is a proprietary combination of cannabidiol-rich oil and CannAmide, SciSparc's palmitoylethanolamide-based tablets. The randomized, double-blind, placebo-controlled trial with cross-over will span 20 weeks and enroll 60 children. Primary efficacy endpoints include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement scale, and determining the effective therapeutic dosage. SciSparc's CEO, Oz Adler, expressed confidence in the treatment's potential to offer a more effective and safe option for patients. The company aims to proceed with the commercialization of SCI-210 in Israel following the trial's outcome. The press release also serves as a forward-looking statement and is incorporated by reference into the company's registration statements filed with the SEC.
SciSparc Ltd., a clinical-stage pharmaceutical company, announced on February 29, 2024, the successful delivery of its SCI-210 treatment for a clinical trial targeting Autism Spectrum Disorder (ASD) in pediatric patients. The trial, to be conducted at the Soroka Medical Center, will test the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy. SCI-210 is a proprietary combination of cannabidiol-rich oil and CannAmide, SciSparc's palmitoylethanolamide-based tablets. The randomized, double-blind, placebo-controlled trial with cross-over will span 20 weeks and enroll 60 children. Primary efficacy endpoints include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement scale, and determining the effective therapeutic dosage. SciSparc's CEO, Oz Adler, expressed confidence in the treatment's potential to offer a more effective and safe option for patients. The company aims to proceed with the commercialization of SCI-210 in Israel following the trial's outcome. The press release also serves as a forward-looking statement and is incorporated by reference into the company's registration statements filed with the SEC.
处于临床阶段的制药公司ScisPARC Ltd. 于2024年2月29日宣布，其针对儿科患者自闭症谱系障碍（ASD）的临床试验成功交付其 SCI-210 疗法。该试验将在索罗卡医疗中心进行，将测试 SCI-210 与 CBD 单一疗法相比的安全性、耐受性和有效性。SCI-210 是富含大麻二酚的油和 ScisPARC 基于棕榈酰乙醇酰胺的片剂 CannaMide 的专有组合。这项交叉的随机、双盲、安慰剂对照试验将持续20周，招收60名儿童。主要疗效终点包括异常行为清单社区、临床全球印象改善量表和确定有效治疗剂量。ScisPARC的首席执行官奥兹·阿德勒表示相信，该疗法有可能为患者提供更有效、更安全的选择。该公司的目标是在试验结果出来后继续在以色列推动 SCI-210 的商业化。该新闻稿还是一份前瞻性声明，并以引用方式纳入公司向美国证券交易委员会提交的注册声明中。
处于临床阶段的制药公司ScisPARC Ltd. 于2024年2月29日宣布，其针对儿科患者自闭症谱系障碍（ASD）的临床试验成功交付其 SCI-210 疗法。该试验将在索罗卡医疗中心进行，将测试 SCI-210 与 CBD 单一疗法相比的安全性、耐受性和有效性。SCI-210 是富含大麻二酚的油和 ScisPARC 基于棕榈酰乙醇酰胺的片剂 CannaMide 的专有组合。这项交叉的随机、双盲、安慰剂对照试验将持续20周，招收60名儿童。主要疗效终点包括异常行为清单社区、临床全球印象改善量表和确定有效治疗剂量。ScisPARC的首席执行官奥兹·阿德勒表示相信，该疗法有可能为患者提供更有效、更安全的选择。该公司的目标是在试验结果出来后继续在以色列推动 SCI-210 的商业化。该新闻稿还是一份前瞻性声明，并以引用方式纳入公司向美国证券交易委员会提交的注册声明中。
有用
没用